Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 May 15;8(1):e000451. doi: 10.1136/jitc-2019-000451

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.

PMC Copyright notice

Correlation of endoscopy data and immunosuppression receipt. (A) Bar graph illustrating the percent of cases of colitis with and without ulceration and immunosuppressive needs. Presence of ulceration (Mayo Endoscopic Score (MES) 3) was associated with use of infliximab (p 0.008). (B) Need for immunosuppression by MES score. MES was significantly higher in patients who received infliximab compared with those who did not (p=0.003) with a median score of 2.5. (C) Differences in immunosuppressive need stratified by MES cohorts (MES 0 and MES 1–3). Nine of 12 (75%) MES grade 3 cases of colitis required infliximab. In contrast, only 18% (2/11) cases classified as MES 0 required tumor necrosis factor (TNF)-α inhibition (p=0.007).